<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082979</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000361751</org_study_id>
    <secondary_id>RMNHS-2282</secondary_id>
    <secondary_id>EU-20351</secondary_id>
    <nct_id>NCT00082979</nct_id>
  </id_info>
  <brief_title>Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer</brief_title>
  <official_title>Evaluation of the Role of Duct Endoscopy in the Assessment of Cellular Atypia Within Breast Duct Fluid in High-Risk Women Carrying BRCA1/2 or p53 Gene Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as breast duct endoscopy, may improve the ability to&#xD;
      detect breast cancer earlier and plan more effective treatment.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well breast duct endoscopy works in assessing&#xD;
      cellular atypia (abnormal cells) in the breast ducts of women with a genetic risk for breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Correlate cell yield and morphology findings from ductal lavage with duct endoscopy&#xD;
           findings and any subsequent surgical pathology findings in high-risk women with BRCA1,&#xD;
           BRCA2, or p53 gene mutations who have cellular atypia.&#xD;
&#xD;
        -  Determine the prevalence of occult breast cancer in patients with cellular atypia&#xD;
           undergoing duct endoscopy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine patient acceptance of duct endoscopy.&#xD;
&#xD;
        -  Perform immunohistochemical analysis (including estrogen receptor, progesterone&#xD;
           receptor, HER2-neu receptor, epidermal growth factor receptor, p53, and proliferation&#xD;
           marker expression) for markers potentially associated with breast cancer in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine potential molecular markers of malignancy by gene methylation, gene&#xD;
           expression, and proteomics in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo nipple aspiration to identify productive ducts and collect fluid&#xD;
      for tumor marker assessment followed by ductal lavage over 15 minutes. Patients undergo duct&#xD;
      endoscopy over approximately 30 minutes under local anesthesia. If no abnormality is found,&#xD;
      duct endoscopy is repeated in 6 months. If the repeat duct endoscopy is normal, patients&#xD;
      continue to undergo nipple aspiration or ductal lavage as specified in protocols RMNHS-2242&#xD;
      and RMNHS-2269. If an abnormality is found during either the initial or repeat duct&#xD;
      endoscopy, patients may undergo further assessment comprising imaging or biopsy and/or&#xD;
      appropriate surgical intervention.&#xD;
&#xD;
      Fluid is analyzed for tumor markers by immunohistochemistry. Candidate genes are analyzed by&#xD;
      gene methylation studies, gene expression arrays, and proteomic analysis.&#xD;
&#xD;
      Patients are followed for at least 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45-60 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of cell yields and morphology from ductal lavage vs the ductal anatomy visualized at duct endoscopy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of occult pathology (malignant and benign) as assessed by duct endoscopy on intraduct sampling</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity and specificity of ductal lavage to duct endoscopy in detecting atypia or malignancy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of cell yields vs final surgical pathology</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>proteomic profiling</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cytology specimen collection procedure</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>breast duct lavage</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of cellular atypia in nipple aspirate or ductal lavage fluid&#xD;
&#xD;
          -  Enrollment on RMNHS-2242 or RMNHS-2269 required&#xD;
&#xD;
          -  No inflammatory breast cancer&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 64&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal Status&#xD;
&#xD;
          -  Any status&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior allergy to eutectic mixture of local anesthetics (EMLAÂ®) cream or lidocaine&#xD;
&#xD;
          -  No severe illness that would preclude study participation&#xD;
&#xD;
          -  No mental illness or handicap that would preclude study compliance&#xD;
&#xD;
          -  No active infection or inflammation in the breast being studied&#xD;
&#xD;
          -  No nursing within the past 12 months&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Not unconscious&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior tamoxifen&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior subareolar surgery (e.g., papilloma resections, biopsies, or fine needle&#xD;
             aspirations) or any other surgery that may disrupt the ductal systems within 2 cm of&#xD;
             the nipple&#xD;
&#xD;
               -  Biopsies and fine needle aspirations &gt; 2 cm from the nipple are allowed&#xD;
&#xD;
          -  No prior breast implantation on proposed lavage side&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior chemopreventative agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Gui, MD, MS, FRCS(Edin), FRCS(Eng)</last_name>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Gui, MD, MS, FRCS(Edin), FRCS(Eng)</last_name>
      <phone>44-20-7808-2783</phone>
      <email>gerald.gui@rmh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

